Gritstone Oncology Inc represents core values of innovation, integrity, and patient-centricity. With a corporate philosophy centered around advancing personalized immunotherapies, Gritstone Oncology aims to revolutionize cancer treatment. By harnessing the power of the immune system, the company focuses on developing novel therapies that target a patient's tumor-specific mutations. Gritstone Oncology's commitment to scientific excellence and dedication to improving patient outcomes drives their groundbreaking research and development efforts. Through their cutting-edge approach, Gritstone Oncology aims to transform the landscape of cancer care and provide hope to patients worldwide.

Gritstone Oncology Inc is primarily present in the United States, focusing on the development and commercialization of personalized cancer immunotherapies.

Gritstone Oncology Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in June 2018, raising substantial capital to support its research and development activities. In 2019, Gritstone Oncology entered into a clinical collaboration with bluebird bio to evaluate the combination therapy for the treatment of advanced solid tumors. Additionally, in 2020, the company announced positive interim data from its Phase 1 study evaluating the investigational personalized immunotherapy, GRANITE-001, for the treatment of advanced solid tumors. Such achievements highlight Gritstone Oncology Inc's progress in developing innovative therapies to address unmet medical needs in oncology.

Gritstone Oncology Inc, based in the United States, is a clinical-stage biotechnology company focused on developing cancer immunotherapies. Founded in 2015, the company utilizes its proprietary EDGE™ artificial intelligence platform to identify potential neoantigens, which are unique markers found on cancer cells. This allows Gritstone Oncology Inc to develop personalized immunotherapies, including next-generation vaccines and cell therapies, targeting these neoantigens. With a strong commitment to improving the lives of cancer patients, Gritstone Oncology Inc aims to advance the field of precision oncology through innovative research and development.

The main competitors of Gritstone Oncology Inc in the market are biopharmaceutical companies such as Merck & Co., Inc., Bristol-Myers Squibb Company, and AstraZeneca PLC. These companies also specialize in the development and commercialization of novel immunotherapies and cancer treatments.

Gritstone Oncology Inc is primarily active in the biotechnology and pharmaceutical industries.

Gritstone Oncology Inc's business model focuses on the development of personalized cancer immunotherapies. The company utilizes its proprietary artificial intelligence (AI) platform, EDGE, to analyze patient-specific tumor antigens, aiming to identify and target these antigens with custom-made immunotherapies. By leveraging advanced technologies and partnerships, Gritstone Oncology aims to deliver innovative treatments that strengthen the immune system's ability to recognize and destroy cancer cells. With a patient-centric approach, Gritstone Oncology strives to improve outcomes and revolutionize the field of cancer immunotherapy.

Gritstone bio hissesinin F/K oranı -0,44.

Gritstone bio KUV 3,34 dir.

Gritstone bio için AlleAktien Kalite Skoru 3/10'dur.

beklenen Gritstone bio cirosu 15,84 Milyon. USD dir.

beklenen Gritstone bio karı -119,30 Milyon. USD olarak gerçekleşmiştir.

Gritstone Oncology Inc is a biopharmaceutical company specializing in the development of personalized cancer therapies. The company was founded in 2015 and is headquartered in Emeryville, California. The goal of Gritstone Oncology is to save lives and reduce the suffering of cancer patients. The business model of Gritstone Oncology is based on the use of machine learning, artificial intelligence, and genomics to understand the patient's immune response to the tumor and develop personalized immune therapies that can block cancer growth. Personalization is achieved through the analysis of the tumor genome and the patient's immune system to identify the unique genetic footprint of the tumor and its interactions with the immune system. An important component of Gritstone Oncology's business model is collaboration with other companies and research institutions. Through partnerships and collaborations, an innovative cancer research network is created to accelerate the development of personalized immune therapies. For example, the company entered into a research collaboration with Nektar Therapeutics in 2018 to develop a personalized immune therapy for various types of cancer. Gritstone Oncology offers various products based on personalized cancer immunotherapy. One important product is the SLATE™ vaccine candidate, which aims to attract T-cells against a person's unique cancer lineage. The company has also developed a proprietary platform called EDGE™, which enables the identification of neoantigen-specific T-cells. With the help of the EDGE™ platform, Gritstone Oncology can provide personalized medicine through reverse genomics and machine learning analyses. Another important component of Gritstone Oncology's business model is the commercialization of its products. The company pursues a strategy to develop its personalized cancer immunotherapies and obtain approvals from the American Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory authorities. Gritstone Oncology's future planning aims to quickly bring the developed immunotherapies to the market to improve the treatment of cancer patients and generate revenues. Overall, Gritstone Oncology's business model is focused on the development of personalized immune therapies based on the analysis of the tumor genome and the patient's immune system. The company collaborates with other companies and research institutions to shorten the development time and maximize the effectiveness of its products. The commercialization of its products aims to ensure that these technologies are quickly available to cancer patients and can also generate revenues.

Gritstone bio, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Gritstone bio için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Gritstone bio şirketinin ISIN kodu US39868T1051’dir.

Gritstone bio 'nin WKN'si A2N4RX 'dir.

Gritstone bio için Ticker GRTS’dir.

Son 12 ay içerisinde Gritstone bio, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Gritstone bio, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Gritstone bio şirketinin mevcut temettü verimi .

Gritstone bio dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Gritstone bio, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Gritstone bio, 'Sağlık' sektörüne atanmıştır.

Son Gritstone bio tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 06.07.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 06.07.2024 olarak gerçekleşti.

2023 yılında Gritstone bio tarafından 0 USD olarak temettüler dağıtıldı.

Gritstone bio hisselerinin temettüleri USD olarak dağıtılır.